Clinical and Metabonomics Study on the Treatment of Heart Failure After Myocardial Infarction With Modified Wenxin Decoction

Inclusion Criteria: * 18-75 years old； * A history of acute myocardial infarction； * Cardiac function Ⅱ - Ⅲ level； * LVEF 50% or less; * Nt-probnp level ≥ 450 pg/ mL； * All men and women can sign the informed consent form. Exclusion Criteria: * Coronary artery bypass grafting was performed within 12 weeks； * Undergo or possibly undergo cardiac resynchronization therapy; * Primary valvular disease, left ventricular outflow tract obstruction, myocarditis, aneurysm, uncontrolled severe arrhythmia, cardiogenic shock, unstable angina pectoris, or acute myocardial infarction; * Having a serious primary liver, kidney or blood system disease or having a serious mental illness or a systemic disease that is out of control; * Serum creatinine \> 194.5 mol/L or serum potassium \> 5.5mmol /L; * The level of alanine aminotransferase or alkaline phosphatase is 1.5 times of the normal upper limit of \>; * Abnormal blood pressure control, systolic blood pressure exceeding 180mmHg or diastolic blood pressure exceeding 110mmHg; * Pregnancy or lactation; Known or suspected allergy to research drugs; To receive another investigational drug within 30 days of randomization or to be unwilling or unable to provide written consent.